A Focus on Intermediate-Risk Acute Myeloid Leukemia: Sub-Classification Updates and Therapeutic Challenges

• Published in: Cancers Vol. 14; no. 17; p. 4166
• Main Authors: Awada, Hassan, Mustafa Ali, Moaath K, Thapa, Bicky, Awada, Hussein, Seymour, Leroy, Liu, Louisa, Gurnari, Carmelo, Kishtagari, Ashwin, Wang, Eunice, Baer, Maria R
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 28-08-2022; MDPI
• Subjects: Acute myeloid leukemia; Bone marrow; Chemotherapy; Classification; Cytogenetics; Genes; Genomics; Hemopoiesis; Karyotypes; Leukemia; Medical prognosis; Mutation; Osteoprogenitor cells; p53 Protein; Patients; Remission (Medicine); Review; Risk groups; United States
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14174166

Acute myeloid leukemia (AML) represents a heterogeneous group of hematopoietic neoplasms deriving from the abnormal proliferation of myeloid progenitors in the bone marrow. Patients with AML may have highly variable outcomes, which are generally dictated by individual clinical and genomic characteristics. As such, the European LeukemiaNet 2017 and 2022 guidelines categorize newly diagnosed AML into favorable-, intermediate-, and adverse-risk groups, based on their molecular and cytogenetic profiles. Nevertheless, the intermediate-risk category remains poorly defined, as many patients fall into this group as a result of their exclusion from the other two. Moreover, further genomic data with potential prognostic and therapeutic influences continue to emerge, though they are yet to be integrated into the diagnostic and prognostic models of AML. This review highlights the latest therapeutic advances and challenges that warrant refining the prognostic classification of intermediate-risk AML.